After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.
Technology & innovation
Initially, a Ford E-Transit fitted with a receiver will be used to gather data as part of a five-year pilot to perfect the technology in real-world settings and study potential public transport applications – though there are plans to open the electric road system to the public within the next few years.
Green ammonia offers a solution to one of the hardest tasks in decarbonization: replacing diesel in large ships. Yara is stepping forward with a commitment to launch the world’s first clean ammonia-powered container ship, ready for service in 2026. Shipping is responsible for between 1.7 and 3% of global CO2 emissions.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.